Our understanding of the hepatic consequences of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection and its resultant coronavirus disease 2019 (COVID …

Viral hepatitis is a major public health threat and a leading cause of death worldwide.
Annual mortality from viral hepatitis is similar to that of other major infectious diseases such …

Pre-existing cross-reactive immune responses to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) proteins in infection-naive subjects have been described by …

Background A safe and efficacious vaccine against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control …

Background The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) might be curtailed by vaccination. We assessed the safety, reactogenicity, and …

Background Older adults (aged≥ 70 years) are at increased risk of severe disease and
death if they develop COVID-19 and are therefore a priority for immunisation should an …

Summary Background The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for
emergency use by the UK regulatory authority, Medicines and Healthcare products …

On 24 th November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B. 1.1.
529 was announced, containing far more mutations in Spike (S) than previously reported …

The Omicron lineage of SARS-CoV-2, which was first described in November 2021, spread
rapidly to become globally dominant and has split into a number of sublineages. BA. 1 …

The race to produce vaccines against severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) began when the first sequence was published, and this forms the basis for …